Treatment of pulmonary arterial hypertension.

By C. Ricachinevsky, S. Amantéa. Jornal de Pediatria, 2006

1,206 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/061c63e0a5272020ec24bb462e50a265da262ac7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, background): “Based on known pathobiological mechanisms of action, three classes of drugs have been extensively studied for treatment of PAH: prostanoids (epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan), and phosphodiesterase inhibitors (sildenafil) (1).”
• Update of EULAR recommendations for the treatment of systemic sclerosis (2015, methodology): “As discussed in previous paragraph, this approach is in line with recently published guidelines regarding management of PAH in general, and seems particularly important in patients with SSc-PAH known to have more progressive disease than patients with other forms of PAH.”
• Pulmonary arterial hypertension in France: results from a national registry. (2006, background): “Because acute vasodilator challenge identifies patients who may benefit from calcium channel blocker therapy, this study confirms that these agents are useful only in a small minority of patients presenting with PAH (8, 11).”
• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, neutral): “Associated with congenital heart disease 5 (2) 4 (2) 1 (1) 3 (2)”
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008, neutral): “Other Nausea 23 (18) 34 (25) 8 (!2 to 18) Edema, peripheral 9 (7) 19 (14) 7 (0 to 15) Edema 8 (6) 17 (13) 7 (0 to 14) Nasal congestion 3 (2) 12 (9) 7 (1 to 12) Upper respiratory tract infection 6 (5) 14 (10) 6 (0 to 12) Asthenia 1 (1) 7 (5) 5 (0 to 9) Chills 0 7 (5) 5 (2 to 9) Gastroesophageal reflu”
• Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension (2005, background): “13 Exclusion criteria were as follows: (1) PAH associated with anorexigens, connective tissue diseases, congenital heart diseases, portal hypertension, or HIV infection; (2) chronic thromboembolic pulmonary hypertension; and (3) other chronic respiratory diseases.”
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 (2008, methodology): “Early escape criteria were (1) 20% decrease in the 6-minute walk distance, (2) an increase in World Health Organization (WHO) functional class,13 (3) a worsening right ventricular failure (as indicated by increased jugular venous pressure, new/worsening hepatomegaly, ascites, or peripheral edema), (”
• Tadalafil Therapy for Pulmonary Arterial Hypertension (2009, neutral): “Anorexigen use 2 (2) 5 (6) 1 (1) 4 (5) 4 (5)”